Immunoglobulin replacement products confer in vivo protection against SARS-CoV-2 XBB.1.5 Omicron variant despite poor neutralizing activity

Zimmerman, Ofer; Altman Doss, Alexa Michelle; Ying, Baoling; Liang, Chieh-Yu; Mackin, Samantha R.; Davis-Adams, Hannah G.; Adams, Lucas J.; VanBlargan, Laura A.; Chen, Rita E.; Scheaffer, Suzanne M.; Desai, Pritesh; Raju, Saravanan; Mantia, Tarisa L.; O'Shaughnessy, Caitlin C.; Monroy, Jennifer M.; Wedner, H. James; Rigell, Christpher J.; Kau, Andrew L.; Dy, Tiffany B.; Ren, Zhen; Turner, Jackson S.; O’Halloran, Jane A.; Presti, Rachel M.; Kendall, Peggy L.; Fremont, Daved H.; Ellebedy, Ali H.; Diamond, Michael S.

Published in

American Society for Clinical Investigation, JCI Insight, 2024

DOI: 10.1172/jci.insight.176359

Tools

Export citation

Search in Google Scholar

Immunoglobulin replacement products confer in vivo protection against SARS-CoV-2 XBB.1.5 Omicron variant despite poor neutralizing activity

Journal article published in 2024 by Ofer Zimmerman, Alexa Michelle Altman Doss, Baoling Ying, Chieh-Yu Liang, Samantha R. Mackin, Hannah G. Davis-Adams

, Lucas J. Adams, Laura A. VanBlargan

, Rita E. Chen

, Suzanne M. Scheaffer, Pritesh Desai, Saravanan Raju, Tarisa L. Mantia, Caitlin C. O'Shaughnessy, Jennifer M. Monroy

and other authors.

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving forbidden

Postprint: archiving forbidden

Published version: archiving allowed

Upload

Policy details

Data provided by

Published in

Links

Tools

Immunoglobulin replacement products confer in vivo protection against SARS-CoV-2 XBB.1.5 Omicron variant despite poor neutralizing activity